Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00668759




Registration number
NCT00668759
Ethics application status
Date submitted
25/04/2008
Date registered
29/04/2008
Date last updated
15/12/2009

Titles & IDs
Public title
A Phase III Superiority Study of Vernakalant vs Amiodarone in Subjects With Recent Onset Atrial Fibrillation
Scientific title
A Phase III Prospective, Randomized, Double-Blind, Active-Controlled, Multi-Center, Superiority Study of Vernakalant Injection Versus Amiodarone in Subjects With Recent Onset Atrial Fibrillation
Secondary ID [1] 0 0
VERI-305-AMIO
Universal Trial Number (UTN)
Trial acronym
AVRO
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Atrial Fibrillation 0 0
Condition category
Condition code
Cardiovascular 0 0 0 0
Other cardiovascular diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Vernakalant Injection
Treatment: Drugs - Amiodarone Injection:

Experimental: 1 - Vernakalant Injection:

In one infusion line, subjects will receive a 10-minute infusion of vernakalant followed by a 15-minute observation period, followed by an additional 10-minute infusion of vernakalant if required (if the subject is still in AF). To maintain blinding, a 60-minute infusion of placebo (D5W) will be administered in a second infusion line, followed by a maintenance infusion of placebo for a minimum of an additional 60 minutes.

Active comparator: 2 - Amiodarone Injection:

In one infusion line subjects will receive a 60-minute infusion of amiodarone followed by a maintenance infusion of amiodarone over an additional 60 minutes. To maintain blinding, a 10-minute infusion of placebo (normal saline) will be administered in a second infusion line, followed by a 15 minute observation period, followed by a 10 minute infusion of placebo if the subject is still in AF.


Treatment: Drugs: Vernakalant Injection
10-minute infusion of 3 mg/kg vernakalant injection followed by a 15-minute observation period, followed by an additional 10-minute infusion of 2 mg/kg of vernakalant if required (if the subject is still in AF).

Treatment: Drugs: Amiodarone Injection:
60-minute infusion of 5 mg/kg amiodarone followed by a maintenance infusion of 50 mg amiodarone over an additional 60 minutes (equivalent to approximately 15 mg/kg over 24 hrs).
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Proportion of subjects with conversion of atrial fibrillation to sinus rhythm within 90 minutes after the start of infusion.
Timepoint [1] 0 0
Conversion of AF to SR for a minimum duration of one minute within 90 minutes after start of infusion.
Secondary outcome [1] 0 0
Time to conversion within 90 minutes after the start of infusion.
Timepoint [1] 0 0
Time to conversion of AF to SR within 90 minutes after start of infusion.
Secondary outcome [2] 0 0
Proportion of subjects with symptom relief at 90 minutes after the start of infusion.
Timepoint [2] 0 0
Relief of AF symptoms 90 minutes after start of infusion.
Secondary outcome [3] 0 0
EQ-5D quality of life assessment.
Timepoint [3] 0 0
Assessment of quality of life 2 hours after start of infusion.
Secondary outcome [4] 0 0
Monitoring of adverse events, vital signs, continuous telemetry monitoring, 12-lead Holter monitoring, 12-lead ECGs, and laboratory tests.
Timepoint [4] 0 0
Specified safety assessments completed at specified time points throughout the study from Screening to Discharge, at the Day 7 visit, and at the Day 30 follow-up call.

Eligibility
Key inclusion criteria
Key

* Have symptomatic AF of 3 to 48 hours duration at baseline.
* Be eligible for cardioversion.
* Have adequate anticoagulation therapy for cardioversion in accordance with standard of practice as recommended by ACC/AHA/ESC guidelines [1].
* Be hemodynamically stable and have systolic blood pressure (BP) above 100 mmHg and less than 160 mmHg and diastolic BP less than 95 mmHg at screening and baseline.

Key
Minimum age
18 Years
Maximum age
85 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Known or suspected prolonged QT or uncorrected QT interval of >440 msec as measured at screening on a 12 lead ECG, familial long QT syndrome, or previous torsades de pointes, ventricular fibrillation; or sustained ventricular tachycardia (VT).
* Symptomatic bradycardia, sick sinus syndrome, or ventricular rate less than 50 beats per minute (bpm) as documented by 12-lead ECG at screening.
* A QRS interval >140 msec.
* Atrial flutter.
* Significant valvular stenosis, hypertrophic obstructive cardiomyopathy, restrictive cardiomyopathy or constrictive pericarditis.
* Documented previous episodes of second or third degree atrioventricular (AV) block.
* Had a myocardial infarction (MI), acute coronary syndrome or cardiac surgery within 30 days prior to entry into the study.
* Uncorrected electrolyte imbalance of serum potassium or magnesium. Both K+ and Mg2+ must be corrected prior to dosing.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/04/2008
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/11/2009
Sample size
Target
Accrual to date
Final
254
Recruitment in Australia
Recruitment state(s)
SA,TAS,WA
Recruitment hospital [1] 0 0
Royal Adelaide Hospital - Adelaide
Recruitment hospital [2] 0 0
Royal Hobart Hospital Cardiology Research - Hobart
Recruitment hospital [3] 0 0
Launceston General Hospital Cardiac Research Unit - Launceston
Recruitment hospital [4] 0 0
Royal Perth Hospital Emergency Research - Perth
Recruitment postcode(s) [1] 0 0
5000 - Adelaide
Recruitment postcode(s) [2] 0 0
7000 - Hobart
Recruitment postcode(s) [3] 0 0
- Launceston
Recruitment postcode(s) [4] 0 0
6000 - Perth
Recruitment outside Australia
Country [1] 0 0
Canada
State/province [1] 0 0
Ontario
Country [2] 0 0
Canada
State/province [2] 0 0
Quebec
Country [3] 0 0
Czech Republic
State/province [3] 0 0
Caslav
Country [4] 0 0
Czech Republic
State/province [4] 0 0
Kromeríž
Country [5] 0 0
Czech Republic
State/province [5] 0 0
Kutna Hora
Country [6] 0 0
Czech Republic
State/province [6] 0 0
Nove Mesto
Country [7] 0 0
Czech Republic
State/province [7] 0 0
Praha
Country [8] 0 0
Czech Republic
State/province [8] 0 0
Pribram
Country [9] 0 0
Czech Republic
State/province [9] 0 0
Semily
Country [10] 0 0
Czech Republic
State/province [10] 0 0
Slaný
Country [11] 0 0
Czech Republic
State/province [11] 0 0
Tabor
Country [12] 0 0
Czech Republic
State/province [12] 0 0
Uherské Hradiste
Country [13] 0 0
Denmark
State/province [13] 0 0
Hellerup
Country [14] 0 0
Denmark
State/province [14] 0 0
Herlev
Country [15] 0 0
Denmark
State/province [15] 0 0
Hjorring
Country [16] 0 0
Denmark
State/province [16] 0 0
Koge
Country [17] 0 0
Denmark
State/province [17] 0 0
Silkeborg
Country [18] 0 0
Estonia
State/province [18] 0 0
Haabneeme
Country [19] 0 0
Estonia
State/province [19] 0 0
Parnu
Country [20] 0 0
Estonia
State/province [20] 0 0
Tallinn
Country [21] 0 0
Estonia
State/province [21] 0 0
Tartu
Country [22] 0 0
Finland
State/province [22] 0 0
Oulu
Country [23] 0 0
France
State/province [23] 0 0
Chambray-les-Tours
Country [24] 0 0
France
State/province [24] 0 0
Nancy
Country [25] 0 0
France
State/province [25] 0 0
Paris
Country [26] 0 0
France
State/province [26] 0 0
Strasbourg
Country [27] 0 0
Germany
State/province [27] 0 0
Berlin
Country [28] 0 0
Germany
State/province [28] 0 0
Bernau
Country [29] 0 0
Germany
State/province [29] 0 0
Bonn
Country [30] 0 0
Germany
State/province [30] 0 0
Frankfurt
Country [31] 0 0
Germany
State/province [31] 0 0
Gottingen
Country [32] 0 0
Germany
State/province [32] 0 0
Halle
Country [33] 0 0
Germany
State/province [33] 0 0
Hamburg
Country [34] 0 0
Germany
State/province [34] 0 0
Hannover
Country [35] 0 0
Germany
State/province [35] 0 0
Kassel
Country [36] 0 0
Germany
State/province [36] 0 0
Köln
Country [37] 0 0
Germany
State/province [37] 0 0
Ludwigshafen
Country [38] 0 0
Germany
State/province [38] 0 0
Merseburg
Country [39] 0 0
Germany
State/province [39] 0 0
Pirna
Country [40] 0 0
Germany
State/province [40] 0 0
Reinbek
Country [41] 0 0
Germany
State/province [41] 0 0
Stuttgart
Country [42] 0 0
Latvia
State/province [42] 0 0
Riga
Country [43] 0 0
Lithuania
State/province [43] 0 0
Kaunas
Country [44] 0 0
Lithuania
State/province [44] 0 0
Klaipeda
Country [45] 0 0
Lithuania
State/province [45] 0 0
Vilnius
Country [46] 0 0
Netherlands
State/province [46] 0 0
Arnhem
Country [47] 0 0
Netherlands
State/province [47] 0 0
Eindhoven
Country [48] 0 0
Netherlands
State/province [48] 0 0
Gouda
Country [49] 0 0
Netherlands
State/province [49] 0 0
Hoogeveen
Country [50] 0 0
Netherlands
State/province [50] 0 0
Maastricht
Country [51] 0 0
Netherlands
State/province [51] 0 0
Nijmegen
Country [52] 0 0
Netherlands
State/province [52] 0 0
Rotterdam
Country [53] 0 0
Poland
State/province [53] 0 0
Bydgoszcz
Country [54] 0 0
Poland
State/province [54] 0 0
Gdynia
Country [55] 0 0
Poland
State/province [55] 0 0
Lodz
Country [56] 0 0
Poland
State/province [56] 0 0
Lublin
Country [57] 0 0
Poland
State/province [57] 0 0
Tarnow
Country [58] 0 0
Poland
State/province [58] 0 0
Torun
Country [59] 0 0
Poland
State/province [59] 0 0
Warszawa
Country [60] 0 0
Poland
State/province [60] 0 0
Wroclaw
Country [61] 0 0
Serbia
State/province [61] 0 0
Belgrade
Country [62] 0 0
Serbia
State/province [62] 0 0
Niska Banja
Country [63] 0 0
Serbia
State/province [63] 0 0
Zemun
Country [64] 0 0
Slovakia
State/province [64] 0 0
Banska Bysterica
Country [65] 0 0
Slovakia
State/province [65] 0 0
Bojnice
Country [66] 0 0
Slovakia
State/province [66] 0 0
Bratislava
Country [67] 0 0
Slovakia
State/province [67] 0 0
Liptovsky Mikulas
Country [68] 0 0
Slovakia
State/province [68] 0 0
Nitra
Country [69] 0 0
Slovakia
State/province [69] 0 0
Ruzomberok
Country [70] 0 0
Slovakia
State/province [70] 0 0
Trnava
Country [71] 0 0
Slovakia
State/province [71] 0 0
Žilina
Country [72] 0 0
Sweden
State/province [72] 0 0
Malmo
Country [73] 0 0
Sweden
State/province [73] 0 0
Orebro
Country [74] 0 0
Sweden
State/province [74] 0 0
Uppsala
Country [75] 0 0
Ukraine
State/province [75] 0 0
Donetsk
Country [76] 0 0
Ukraine
State/province [76] 0 0
Kharkiv
Country [77] 0 0
Ukraine
State/province [77] 0 0
Kiev
Country [78] 0 0
Ukraine
State/province [78] 0 0
Lugansk
Country [79] 0 0
Ukraine
State/province [79] 0 0
Lviv
Country [80] 0 0
Ukraine
State/province [80] 0 0
Odessa

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Advanz Pharma
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Tomas Janota, MD
Address 0 0
VFN III. interní klinika
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT00668759